Erdheim-Chester disease: A challenging diagnosis for an effective therapy
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Clinical Neurology and Neurosurgery
- Vol. 194, 105841
- https://doi.org/10.1016/j.clineuro.2020.105841
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- CNS Erdheim–Chester Disease: A Challenge to DiagnoseJournal of Neuropathology and Experimental Neurology, 2017
- Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester diseaseBritish Journal of Haematology, 2016
- Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trialBlood, 2015
- Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseBlood, 2014
- Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutationBlood, 2013
- CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patientsBlood, 2011
- CHARACTERISTIC BRAIN MRI APPEARANCE OF ERDHEIM-CHESTER DISEASENeurology, 2009